News

Continuing its support of a collaborative Parkinson’s disease (PD) study, the Luxembourg National Research Fund (FNR) has awarded the National Centre for Excellence in Research on Parkinson’s Disease (NCER-PD) €6 million ($6.68 million) for its second phase. Comprised primarily of five research partners, the four-year-old Luxembourg-based NCER-PD is…

Therapies against motor loss and progression in Parkinson’s’ disease (PD) may need to tackle the imbalance between two neurotransmitters, dopamine and acetylcholine, instead of focusing on dopamine alone, an early study suggests. The study, “Dopamine Deficiency Reduces Striatal Cholinergic Interneuron Function in Models of Parkinson’s Disease,” was published…

Widening efforts to give Parkinson’s disease patients access to high-quality speech therapy, the Parkinson Voice Project (PVP) has named the Andrews University School of Communication Sciences & Disorders (SCSD) a recipient of this year’s SPEAK OUT! & LOUD Crowd Grant Program. As is the case with all awardees, the…

Treatment with the naturally occurring antioxidant N-acetylcysteine (NAC) along with standard Parkinson’s therapies improved patients’ motor and mental abilities, possibly by restoring the function of dopamine-producing nerve cells, according to new research. The study, “N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson’s Disease,” appeared in…